-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $810

Benzinga·05/01/2025 14:48:50
Listen to the news
Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $940 to $810.